oral tirzepatide eli lilly gets nod to launch weight-loss drug in Hong Kong Lilly's Oral GLP-1 Drug Shows

During the trial, published in the New England Journal of Medicine , researchers at Northwestern University in Chicago tested semaglutide at a much higher dose as an anti-obesity medication

Freeman, MD, PhD

Nematizadeh, M., Ghorbanzadeh, H., Moghaddam, H

Step 1: Activate Fit ON delivers six synergistic botanicals per serving that work together to help support natural GLP-1 pathways and receptor sensitivity

Tirzepatide is a once-weekly injectable medication primarily used to treat type 2 diabetes and has shown significant benefits for weight loss as well

Additionally, appropriate human longitudinal studies and standardized protocols for measuring durability and safety of microbiota-based interventions among different patient populations will be important